Walleye Capital
UNCY icon

Walleye Capital’s Unicycive Therapeutics UNCY Stock Holding History

Walleye Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-409,426
Closed -$2.35M – 5064
2025
Q1 		$2.35M Sell
409,426
-90,574
-18% -$552K 0.01% 1297
2024
Q4 		$3.97M Hold
500,000
– – 0.01% 1246
2024
Q3 		$2.04M Buy
+500,000
New +$2.01M ﹤0.01% 1935

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's UNCY Position: Q2 2025 in Review

Walleye Capital sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 409,426 shares — an estimated $2.35M sold.

Walleye Capital first reported a position in UNCY in Q3 2024 and held it in 3 quarters. The position peaked at $3.97M in Q4 2024. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

  • Walleye Capital reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 409,426 Unicycive Therapeutics shares in Q2 2025, an estimated $2.35M.
  • Walleye Capital first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 3 quarters.
  • Walleye Capital's Unicycive Therapeutics position peaked at $3.97M in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.